Payment overview · 2025
General Payments
$661.74
34 reported records · 14 companies
Healthcare provider profile · identity verified
Michael Gunter, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · OPELIKA, AL · NPI 1780765669
Verified facts
What the public records show
CMS Open Payments records show Michael Gunter, M.D. received $661.74 in general payments during 2025 across 34 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Shingrix, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 176 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $175.46 | 26.5% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $102.71 | 15.5% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $65.51 | 9.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $63.88 | 9.7% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $45.61 | 6.9% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $41.45 | 6.3% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.43 | 5.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.55 | 4.9% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $19.22 | 2.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.51 | 2.8% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $16.81 | 2.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.33 | 2.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.72 | 2.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.55 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $661.74 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $175.46 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $102.71 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $84.52 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $65.51 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $63.88 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $49.11 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $45.61 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $41.45 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $35.43 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.55 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $16.81 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.33 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.33 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 176 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 80 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 212 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 159 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
80 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
212 | 39 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
57 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
159 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
31 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
176 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 940 | 258 |
| Atorvastatin Calcium | Atorvastatin Calcium | 827 | 222 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 752 | 216 |
| Pantoprazole Sodium | Pantoprazole Sodium | 584 | 165 |
| Levothyroxine Sodium | Levothyroxine Sodium | 539 | 139 |
| Losartan Potassium | Losartan Potassium | 500 | 143 |
| Gabapentin | Gabapentin | 486 | 124 |
| Lisinopril | Lisinopril | 404 | 98 |
| Metoprolol Succinate | Metoprolol Succinate | 364 | 88 |
| Mounjaro | Tirzepatide | 356 | 48 |
| Simvastatin | Simvastatin | 318 | 83 |
| Hydrochlorothiazide | Hydrochlorothiazide | 311 | 83 |
| Omeprazole | Omeprazole | 302 | 86 |
| Alprazolam | Alprazolam | 239 | 49 |
| Potassium Chloride | Potassium Chloride | 232 | 76 |
| Zolpidem Tartrate | Zolpidem Tartrate | 232 | 36 |
| Metformin Hcl Er | Metformin Hcl | 229 | 69 |
| Jardiance | Empagliflozin | 212 | 39 |
| Meloxicam | Meloxicam | 204 | 75 |
| Valsartan | Valsartan | 198 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 197 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 183 | 55 |
| Metformin Hcl | Metformin Hcl | 179 | 52 |
| Lorazepam | Lorazepam | 178 | 30 |
| Eliquis | Apixaban | 176 | 31 |
| Memantine Hcl | Memantine Hcl | 176 | 32 |
| Trazodone Hcl | Trazodone Hcl | 171 | 58 |
| Famotidine | Famotidine | 169 | 50 |
| Mirtazapine | Mirtazapine | 168 | 43 |
| Tramadol Hcl | Tramadol Hcl | 168 | 39 |
| Ozempic | Semaglutide | 159 | 29 |
| Donepezil Hcl | Donepezil Hcl | 152 | 33 |
| Buspirone Hcl | Buspirone Hcl | 142 | 36 |
| Allopurinol | Allopurinol | 136 | 39 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 136 | 33 |
| Furosemide | Furosemide | 135 | 52 |
| Sertraline Hcl | Sertraline Hcl | 131 | 32 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 129 | 37 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 128 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 58 |
| Fluticasone Propionate | Fluticasone Propionate | 122 | 44 |
| Hydralazine Hcl | Hydralazine Hcl | 122 | 42 |
| Montelukast Sodium | Montelukast Sodium | 116 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 115 | 32 |
| Celecoxib | Celecoxib | 112 | 27 |
| Ezetimibe | Ezetimibe | 112 | 37 |
| Chlorthalidone | Chlorthalidone | 109 | 29 |
| Alendronate Sodium | Alendronate Sodium | 101 | 33 |
| Cephalexin | Cephalexin | 100 | 70 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 22 |
| Doxazosin Mesylate | Doxazosin Mesylate | 97 | 22 |
| Pregabalin | Pregabalin | 95 | 22 |
| Spironolactone | Spironolactone | 95 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 94 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 92 | 83 |
| Fluoxetine Hcl | Fluoxetine Hcl | 82 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 22 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 81 | 21 |
| Farxiga | Dapagliflozin Propanediol | 80 | 15 |
| Carvedilol | Carvedilol | 79 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 23 |
| Clonazepam | Clonazepam | 74 | 12 |
| Methylprednisolone | Methylprednisolone | 71 | 64 |
| Bupropion Xl | Bupropion Hcl | 69 | 22 |
| Atenolol | Atenolol | 67 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 67 | 15 |
| Mupirocin | Mupirocin | 66 | 49 |
| Warfarin Sodium | Warfarin Sodium | 65 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 62 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 61 | 24 |
| Benazepril Hcl | Benazepril Hcl | 58 | 17 |
| Prednisone | Prednisone | 58 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 24 |
| Lovastatin | Lovastatin | 57 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 16 |
| Synthroid | Levothyroxine Sodium | 56 | 15 |
| Estradiol | Estradiol | 55 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 49 | 14 |
| Nifedipine Er | Nifedipine | 47 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 12 |
| Ketoconazole | Ketoconazole | 46 | 19 |
| Bumetanide | Bumetanide | 44 | 12 |
| Glimepiride | Glimepiride | 44 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 44 | suppressed |
| Ramipril | Ramipril | 44 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 12 |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 12 |
| Meclizine Hcl | Meclizine Hcl | 41 | 18 |
| Valacyclovir | Valacyclovir Hcl | 41 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 39 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 38 | 13 |
| Fluconazole | Fluconazole | 37 | 20 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 37 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 31 | 31 |
| Ondansetron Odt | Ondansetron | 31 | 25 |
| Finasteride | Finasteride | 30 | 11 |
| Colchicine | Colchicine | 29 | 16 |
| Terbinafine Hcl | Terbinafine Hcl | 28 | 12 |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Azithromycin | Azithromycin | 25 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 22 |
| Klor-Con 10 | Potassium Chloride | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 18 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Trimethoprim | Trimethoprim | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 19 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 18 | 18 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 14 |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 12 | 11 |
| Nadolol | Nadolol | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $661.74 · 34 records | AstraZeneca Pharmaceuticals LP | AREXVY, AUSTEDO XR, CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, GVOKE HYPOPEN, JARDIANCE, Kerendia, NURTEC ODT, Ozempic, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, Tymlos, XIFAXAN, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error